Stay updated with breaking news from Pharma Sector. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sun Pharmaceutical Industries plans to acquire all outstanding shares of Taro Pharmaceutical Industries for $43 per share in cash, aiming to gain complete control over its subsidiary
In 2012, a parliamentary standing committee of the health ministry had observed in its report that some of the state licensing authorities issued manufacturing licences for a large number of FDCs without prior clearance from the central drug authority, resulting in the availability of several FDCs which were not tested for safety and efficacy.
Milind Karmarkar says: “In mid and especially smallcaps, there are excesses. It may continue for a long time, because I have learned that during the software boom, when you think there are excesses, the market, the prices can grow four times from there. As a fund manager, I would not get into that at all.”
Nithya Balasubramanian says: “At a top-down level, there is a lot more growth than what we are seeing in data. But I believe that the growth drivers will possibly shift into volume growth from pricing growth. The last two years have been pretty good in terms of pricing growth because of the higher inflation as well which was passed along.”
“For one week or so, probably the market could be range-bound or and there is scope for some profit booking at this point. So, I am not very bullish, although the trend is going up but with less momentum. So there is some scope for profit booking. I do not see a lot of upside at this moment. I would be a little neutral at this point in time.”